We are live on ! Find out more
BCM

Boxer Capital Management Portfolio holdings

AUM $762M
1-Year Est. Return 1,125.36%
This Fund
S&P 500
This Quarter Est. Return
+89.98%
1 Year Est. Return
+1,125.36%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$199M
AUM Growth
-$134M
Cap. Flow
-$197M
Cap. Flow %
-99.18%
Top 10 Hldgs %
91.42%
Holding
36
New
8
Increased
3
Reduced
7
Closed
16

Top Buys

Rank Stock Value
1
CBIO
Crescent Biopharma
CBIO
+$9.6M
2
ITOS
iTeos Therapeutics
ITOS
+$6.65M
3
URGN icon
UroGen Pharma
URGN
+$5.52M
4
KYMR icon
Kymera Therapeutics
KYMR
+$3.68M
5
REPL icon
Replimune Group
REPL
+$3.62M

Top Sells

Rank Stock Value
1
NUVL
Nuvalent
NUVL
+$31.9M
2
RNAM
Avidity Biosciences
RNAM
+$25.5M
3
ANAB icon
AnaptysBio
ANAB
+$24.2M
4
RVMD icon
Revolution Medicines
RVMD
+$20.2M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$20.1M

Sector Composition

Rank Sector Weight
1 Healthcare 99.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
26
Legend Biotech
LEGN
$3.65B
– –
-200,000
Closed -$6.79M
NUVL
27
DELISTED
Nuvalent
NUVL
– –
-450,000
Closed -$31.9M
ORIC icon
28
Oric Pharmaceuticals
ORIC
$1.17B
– –
-1,732,571
Closed -$9.67M
PRLD icon
29
Prelude Therapeutics
PRLD
$375M
– –
-2,108,014
Closed -$1.62M
PRTA icon
30
Prothena Corp
PRTA
$448M
– –
-690,000
Closed -$8.54M
RNAM
31
DELISTED
Avidity Biosciences
RNAM
– –
-865,000
Closed -$25.5M
SLDB icon
32
Solid Biosciences
SLDB
$792M
– –
-1,240,700
Closed -$4.59M
XENE icon
33
Xenon Pharmaceuticals
XENE
$6.1B
– –
-600,000
Closed -$20.1M
BOLD
34
Boundless Bio
BOLD
$55.7M
– –
-250,000
Closed -$378K
CLYM
35
Climb Bio
CLYM
$693M
– –
-145,000
Closed -$177K
CMRX
36
DELISTED
Chimerix, Inc.
CMRX
– –
-1,810,000
Closed -$15.4M
1
2

Similar funds

GWM
Gibbs Wealth Management Alpharetta, Georgia $762M AUM 18.55% 1-Year Est. Return
FTF
Freedom Together Foundation New York $762M AUM 15.13% 1-Year Est. Return
TI
Think Investments San Francisco, California $762M AUM 33.1% 1-Year Est. Return
CFS
Cannon Financial Strategists Athens, Georgia $761M AUM 18.73% 1-Year Est. Return
PMWMG
Parr McKnight Wealth Management Group Minneapolis, Minnesota $763M AUM 13.49% 1-Year Est. Return
FCA
Fortis Capital Advisors Prairie Village, Kansas $763M AUM 30.51% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SIG
Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

Boxer Capital Management's Q2 2025 Portfolio in Review

As of Q2 2025, Boxer Capital Management held 36 positions worth $199M, down 40% from $332M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Boxer Capital Management withdrew a net $197M in Q2 2025, closing 16 positions and reducing 7 holdings. Its most notable exit was Nuvalent, an estimated $31.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier.

Against the trend, Boxer Capital Management opened a new position in Crescent Biopharma worth $7.32M.

  • Boxer Capital Management's largest Q2 2025 buy was Crescent Biopharma: 453,686 shares worth $7.32M.
  • Boxer Capital Management added most to Kymera Therapeutics in Q2 2025, an estimated $3.68M increase.
  • Boxer Capital Management's biggest Q2 2025 reduction was Revolution Medicines, cutting an estimated $20.2M.
  • Boxer Capital Management fully exited Nuvalent in Q2 2025, selling an estimated $31.9M.
  • Boxer Capital Management's ten largest holdings make up 91% of its $199M portfolio in Q2 2025.
  • Boxer Capital Management opened 8 new positions and closed 16 in Q2 2025.
  • Boxer Capital Management's portfolio value fell 40% quarter-over-quarter to $199M.

Based on Boxer Capital Management's 13F filing for Q2 2025, filed 14 Aug 2025.